ARTICLE | Company News
Neurocrine, Janssen Pharmaceutica Inc. deal
April 15, 2013 7:00 AM UTC
NBIX received an undisclosed milestone from Janssen for starting a Phase I trial of NBI-30775 (R121919), a corticotropin releasing factor (CRF) receptor antagonist for anxiety and depression (see C5)...